Lipocine Inc. (LPCN)

Price$2.05

Value ScoreB

Growth ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-48.33%

Price vs S&P 500 (4W)-13.49%

VGM Score51.70

Market Capitalization$16.90M

P/E Ratio (Annual)6416.73x

All Metrics

Book Value / Share (Quarterly)$3.05

P/TBV (Annual)0.37x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)58.12%

Cash Flow / Share (Quarterly)$-1.34

Price vs S&P 500 (YTD)-82.63%

Net Profit Margin (TTM)-571.09%

EPS (TTM)$-1.96

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-1.96

Revenue Growth (5Y)133.89%

EPS (Annual)$-1.77

ROI (Annual)-66.50%

Net Profit Margin (5Y Avg)-2154.83%

Cash / Share (Quarterly)$3.31

Revenue Growth QoQ (YoY)27.21%

P/E Normalized (Annual)6416.73x

ROA (Last FY)-56.61%

Revenue Growth TTM (YoY)-45.52%

EBITD / Share (TTM)$-2.08

ROE (5Y Avg)-35.66%

Operating Margin (TTM)-605.86%

Cash Flow / Share (Annual)$-1.58

P/B Ratio0.74x

P/B Ratio (Quarterly)2.62x

Net Income / Employee (Annual)$-687,700

EV / Revenue (TTM)5.94x

Net Interest Coverage (TTM)-3.50x

ROA (TTM)-59.39%

EV / EBITDA (TTM)3.42x

EPS Incl Extra (Annual)$-1.77

Current Ratio (Annual)6.68x

Quick Ratio (Quarterly)9.87x

3-Month Avg Trading Volume0.31M

52-Week Price Return-34.34%

Revenue / Employee (TTM)$143,000

Tangible BV / Share (Quarterly)$4.23

P/S Ratio (Annual)8.55x

Asset Turnover (Annual)0.12x

52-Week High$12.37

Operating Margin (5Y Avg)-2195.35%

EPS Excl Extra (Annual)$-1.77

Tangible BV CAGR (5Y)13.43%

26-Week Price Return-40.41%

Quick Ratio (Annual)6.36x

13-Week Price Return-74.97%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.99x

Enterprise Value$11.89M

Revenue / Share Growth (5Y)81.34%

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)-8.79%

Revenue / Employee (Annual)$141,200

Pretax Margin (Annual)-487.04%

Cash / Share (Annual)$2.42

3-Month Return Std Dev167.87%

Net Income / Employee (TTM)$-816,800

ROE (Last FY)-66.50%

Net Interest Coverage (Annual)-3.57x

EPS Basic Excl Extra (Annual)$-1.77

P/FCF (TTM)4.13x

Receivables Turnover (TTM)13.79x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.96

Receivables Turnover (Annual)29.36x

ROI (TTM)-66.69%

P/S Ratio (TTM)8.44x

Pretax Margin (5Y Avg)-2154.82%

Revenue / Share (Annual)$0.36

Tangible BV / Share (Annual)$6.84

Price vs S&P 500 (52W)-58.70%

Year-to-Date Return-74.47%

5-Day Price Return-10.09%

EPS Normalized (Annual)$-1.77

ROA (5Y Avg)-31.50%

Net Profit Margin (Annual)-487.05%

Month-to-Date Return-8.89%

Cash Flow / Share (TTM)$-3.09

EBITD / Share (Annual)$-1.89

Operating Margin (Annual)-524.69%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-35.65%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.96

P/TBV (Quarterly)0.59x

P/B Ratio (Annual)3.08x

Pretax Margin (TTM)-571.09%

Book Value / Share (Annual)$2.35

Price vs S&P 500 (13W)-83.22%

Beta0.46x

Revenue / Share (TTM)$0.29

ROE (TTM)-66.69%

52-Week Low$1.81

vGradeB

gGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.54est. -0.49

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.13

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
LPCNLipocine Inc.	B	B	D	$2.05
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Lipocine is a clinical-stage biopharmaceutical company developing oral drug delivery solutions using proprietary technology. Its lead product, TLANDO, is an oral testosterone replacement therapy. The company is advancing a pipeline of additional candidates including TLANDO XR and compounds designated LPCN 1144, LPCN 1148, LPCN 1107, and LPCN 1154, developed both internally and in collaboration with corporate partners.